Eversept Partners LP Takes Position in Ascendis Pharma A/S $ASND

Eversept Partners LP purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 48,241 shares of the biotechnology company’s stock, valued at approximately $10,287,000. Eversept Partners LP owned approximately 0.08% of Ascendis Pharma A/S at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisory Services Network LLC bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at $26,000. Arax Advisory Partners increased its holdings in Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after buying an additional 104 shares in the last quarter. Leonteq Securities AG bought a new stake in Ascendis Pharma A/S in the 4th quarter worth about $36,000. Global Retirement Partners LLC increased its holdings in Ascendis Pharma A/S by 111.9% in the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after buying an additional 113 shares in the last quarter. Finally, GW&K Investment Management LLC increased its holdings in Ascendis Pharma A/S by 75.2% in the 4th quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after buying an additional 97 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently commented on ASND shares. Evercore reiterated an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, May 15th. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Oppenheimer reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Citigroup started coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Finally, Jefferies Financial Group started coverage on Ascendis Pharma A/S in a report on Monday, March 16th. They issued a “buy” rating and a $290.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $295.39.

Insider Transactions at Ascendis Pharma A/S

In other news, Director Jean Jacques Bienaime purchased 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was acquired at an average cost of $237.80 per share, for a total transaction of $95,120.00. Following the purchase, the director directly owned 400 shares in the company, valued at $95,120. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The SEC filing for this sale provides additional information. Insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Trading Down 0.0%

Ascendis Pharma A/S stock opened at $231.15 on Thursday. The business has a 50-day simple moving average of $232.16 and a two-hundred day simple moving average of $224.09. The company has a market cap of $14.42 billion, a P/E ratio of 26.66 and a beta of 0.39. Ascendis Pharma A/S has a 52-week low of $160.86 and a 52-week high of $250.74. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. Analysts predict that Ascendis Pharma A/S will post 14.25 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.